Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654287 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2HPGDESR1 | |
| SCHEMBL1654169 | 0.86 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL4521603 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDESR1 | |
| SCHEMBL1653484 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDESR1 | |
| SCHEMBL1654198 | 0.84 | KDM4E (0.35) | KDM4EALDH1A1SMN1; SMN2HPGDESR1 | |
| SCHEMBL13675256 | 0.84 | ALDH1A1 (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL12784632 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2NPC1TSHRTP53 | |
| SCHEMBL1653505 | 0.82 | TSHR (0.40) | KDM4EALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL13675005 | 0.80 | NFKBIA (0.43) | KDM4EALDH1A1HPGDESR1NPC1 | |
| SCHEMBL13221717 | 0.80 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2HPGDNPC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | KDM4E 1299/4885ALDH1A1 372/4885SMN1; SMN2 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.